Abstract
Up to date, imaging presents especially a supportive role in bladder cancer (BCa) diagnostic workup, even if it is essential in the staging phase. In fact, the final diagnosis always implicates cystoscopy.
In case of suspected BCa, CT with and without contrast media intravenous injection should always include the study of the excretory phase, obtaining computed tomography urography (CTU). This technique has the aim to investigate the urinary tract, searching the presence of papillary tumors, which usually appears as filling defects and/or hydronephrosis.
Multi-parametric MRI (mpMRI) shows an extremely powerful potential in the detection, description, and classification of BCa, even if it is not yet widely introduced in the international guidelines. The principal role of MRI is the local tumor staging, which is paramount to plan the most suitable treatment. Moreover, it can help to differentiate between NMIBC and MIBC, which is mandatory, because it changes the treatment planning.
The promising performance of mpMRI of the bladder led to the designing of the Vesical Imaging Reporting and Data System (VI-RADS) score. This new scoring system has the aim to standardize the approach to imaging and reporting of mp-MRI for BCa and to define the risk of muscle invasion.
The use of VI-RADS is now especially dedicated to the pre-TURBT workup and before intravesical BCG (Bacillus Calmette-Guerin) injection. Preoperative MRI and VI-RADS score give interesting and useful information in the evaluation of treatment response, indicating when BCa requires a more aggressive approach. Furthermore, in cases of high-risk NMIBC, VI-RADS score may play a useful role also for disease risk stratification and as an indicator of whether a secondary excision of the tumor is necessary. The high risk of tumor recurrence and the frequent necessity for a secondary tumor resection stimulate its application as a follow-up diagnostic tool.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Panebianco V, Pecoraro M, Del Giudice F, et al. VI-RADS for bladder cancer: current applications and future developments. J Magn Reson Imaging JMRI. 2020; https://doi.org/10.1002/jmri.27361.
Sam P, Nassereddin A, LaGrange CA. Anatomy, abdomen and pelvis, bladder detrusor muscle. Treasure Island, FL: StatPearls; 2021.
Shermadou ES, Rahman S, Leslie SW. Anatomy, abdomen and pelvis, bladder. Treasure Island, FL: StatPearls; 2021.
Bolla SR, Jetti R. Histology bladder. Treasure Island, FL: StatPearls; 2020. http://www.ncbi.nlm.nih.gov/books/NBK540963/
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.
Herr H. Preventable cancer deaths associated with bladder preservation for muscle invasive bladder cancer. Urology. 2019;130:20–1. https://doi.org/10.1016/j.urology.2019.04.032.
Elsholtz FHJ, Asbach P, Haas M, et al. Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol. 2021; https://doi.org/10.1007/s00330-020-07572-4.
Choyke PL. Radiologic evaluation of hematuria: guidelines from the American College of Radiology’s appropriateness criteria. Am Fam Physician. 2008;78:347–52.
Hilton S, Jones LP. Recent advances in imaging cancer of the kidney and urinary tract. Surg Oncol Clin N Am. 2014;23:863–910. https://doi.org/10.1016/j.soc.2014.06.001.
CT Urography Working Group of the European Society of Urogenital Radiology (ESUR), Van Der Molen AJ, Cowan NC, et al. CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol. 2008;18:4–17. https://doi.org/10.1007/s00330-007-0792-x.
On behalf of the “French Society of Genitourinary Imaging Consensus group,” Renard-Penna R, Rocher L, et al. Imaging protocols for CT urography: results of a consensus conference from the French Society of Genitourinary Imaging. Eur Radiol. 2020;30:1387–1396. https://doi.org/10.1007/s00330-019-06529-6
Wong VK, Ganeshan D, Jensen CT, Devine CE. Imaging and management of bladder cancer. Cancers. 2021;13:1396. https://doi.org/10.3390/cancers13061396.
Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018;74:294–306. https://doi.org/10.1016/j.eururo.2018.04.029.
Blick CGT, Nazir SA, Mallett S, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 2012;110:84–94. https://doi.org/10.1111/j.1464-410X.2011.10664.x.
Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204:778–86. https://doi.org/10.1097/JU.0000000000001297.
Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329–54. https://doi.org/10.6004/jnccn.2020.0011.
NICE (National Institute for Health and Care Excellence) Guideline. Bladder cancer: diagnosis and management. 2015.
Juri H, Narumi Y, Valeria P, Osuga K. Staging of bladder cancer with multiparametric MRI. Br J Radiol. 2020;93:20200116. https://doi.org/10.1259/bjr.20200116.
Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. RadioGraphics. 2012;32:371–87. https://doi.org/10.1148/rg.322115125.
de Haas RJ, Steyvers MJ, Fütterer JJ. Multiparametric MRI of the bladder: ready for clinical routine? Am J Roentgenol. 2014;202:1187–95. https://doi.org/10.2214/AJR.13.12294.
Panebianco V, Barchetti F, de Haas RJ, et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging. Eur Urol Focus. 2016;2:113–21. https://doi.org/10.1016/j.euf.2016.04.010.
Narumi Y, Kadota T, Inoue E, et al. Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology. 1993;187:151–5. https://doi.org/10.1148/radiology.187.1.8451403.
Panebianco V, De Berardinis E, Barchetti G, et al. An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol. 2017;27:3759–66. https://doi.org/10.1007/s00330-017-4758-3.
Zhou G, Chen X, Zhang J, et al. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol. 2014;83:2013–8. https://doi.org/10.1016/j.ejrad.2014.08.012.
Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol. 2019;92:20190401. https://doi.org/10.1259/bjr.20190401.
Kobayashi S, Koga F, Yoshida S, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol. 2011;21:2178–86. https://doi.org/10.1007/s00330-011-2174-7.
Yoshida S, Koga F, Kawakami S, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology. 2010;75:387–91. https://doi.org/10.1016/j.urology.2009.06.111.
Nguyen HT, Mortazavi A, Pohar KS, et al. Quantitative assessment of heterogeneity in bladder tumor MRI diffusivity: can response be predicted prior to neoadjuvant chemotherapy? Bladder Cancer Amst Neth. 2017;3:237–44. https://doi.org/10.3233/BLC-170110.
Necchi A, Bandini M, Calareso G, et al. Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study. Eur Urol. 2020;77:636–43. https://doi.org/10.1016/j.eururo.2019.12.016.
Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology. 1998;207:791–7. https://doi.org/10.1148/radiology.207.3.9609906.
Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1889–94. https://doi.org/10.1200/JCO.2013.52.4785.
Donaldson SB, Bonington SC, Kershaw LE, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013;82:2161–8. https://doi.org/10.1016/j.ejrad.2013.08.008.
Del Giudice F, Leonardo C, Simone G, et al. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease? BJU Int. 2020;126:610–9. https://doi.org/10.1111/bju.15188.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Panebianco, V., Messina, E., Vargas, H.A., Catto, J. (2022). Imaging in Bladder Cancer Surgery. In: Wiklund, P., Mottrie, A., Gundeti, M.S., Patel, V. (eds) Robotic Urologic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-031-00363-9_55
Download citation
DOI: https://doi.org/10.1007/978-3-031-00363-9_55
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-00362-2
Online ISBN: 978-3-031-00363-9
eBook Packages: MedicineMedicine (R0)